FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Novo Nordisk India Sales Jump 40% in April After Wegovy, Ozempic Price Cuts

By

-- Novo Nordisk's diabetes and obesity drug sales recorded a sharp rise in India sales in April after it reduced prices of Wegovy and Ozempic to counter growing competition from generic semaglutide therapies, Bloomberg News reported Friday, citing Pharmarack data.

Sales of Wegovy, Ozempic and partner-branded products climbed 40% monthly to 32,000 units in April, which was the first full month since the Danish pharmaceutical group lowered starter-dose prices by up to 48%, the report noted.

India's overall GLP-1 market expanded 56% month over month in April to 414,000 units, driven by low-cost generic semaglutide products, the report noted. Eli Lilly remained the country's top-selling GLP-1 drugmaker.

Novo Nordisk did not immediately respond to' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Research

Research Alert: Telus Results Impacted By Strong Competition Within Wireless Industry

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:TELUS reported challenging Q1 2026 results with revenue declining 0.6% to $4,989M and EPS falling to $0.09 from $0.21, missing the consensus of $0.22. Earnings declined due to elevated restructuring costs of $315M versus $97M in the prior year and 12.2% equipment revenue drop amid competitive pressures. TELUS Health emerged as the standout with 11.2% growth to $526M, demonstrating strategic diversification value beyond core telecom. Management characterized the wireless environment as "highly promotional and irrational" with aggressive pricing threatening premium brand value. We expect continued margin pressure as competitor price emulation commoditizes benefits and undermines value creation. However, we believe TELUS Health's performance and operational synergies, including $431M in delivered LifeWorks synergies, provide some offset. Net debt to EBITDA improved to 3.5x from 3.9x, progressing toward the 2027 target of approximately 3.0x.

$TU
Equities

Alpha Metallurgical Resources Q1 Loss Narrows, Revenue Falls

Alpha Metallurgical Resources (AMR) reported Friday that it narrowed its Q1 loss to $0.86 per diluted share, compared with a loss of $2.60 a year earlier.Four analysts polled by FactSet expected $0.37.Revenue for the quarter ended March 31 was $525.0 million, compared with $532.0 million a year earlier.Four analysts surveyed by FactSet expected $535.2 million.

$AMR
Mining & Metals

BlackBerry Announcing Renewal of Normal Course Issuer Bid Share Buyback Program

$BB.TO